2018
Prediction of major adverse kidney events in critically ill burn patients
DEPRET, F., L. BOUTIN, Jiří JARKOVSKÝ, M. CHAUSSARD, S. SOUSSI et. al.Základní údaje
Originální název
Prediction of major adverse kidney events in critically ill burn patients
Autoři
DEPRET, F. (250 Francie), L. BOUTIN (250 Francie), Jiří JARKOVSKÝ (203 Česká republika, domácí), M. CHAUSSARD (250 Francie), S. SOUSSI (250 Francie), A. BATAILLE (250 Francie), H. OUESLATI (250 Francie), N. MORENO (250 Francie), C. de TYMOWSKI (250 Francie), Jiří PAŘENICA (203 Česká republika, domácí), Klára BENEŠOVÁ (203 Česká republika, domácí), T. VAUCHEL (250 Francie), A. FERRY (250 Francie), M. BENYAMINA (250 Francie), A. CUPACIU (250 Francie), M. COUTROT (250 Francie), J.P. GARNIER (250 Francie), K. SERROR (250 Francie), M. CHAOUAT (250 Francie), A. MEBAZAA (250 Francie) a M. LEGRAND (250 Francie, garant)
Vydání
Burns, OXFORD, ELSEVIER SCI LTD, 2018, 0305-4179
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30212 Surgery
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.247
Kód RIV
RIV/00216224:14110/18:00104900
Organizační jednotka
Lékařská fakulta
UT WoS
000451331200004
Klíčová slova anglicky
Plasmatic Neutrophil Gelatinase-Associated Lipocain; Acute kidney injury; Burn patients; Major adverse kidney event
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 4. 2024 10:05, Mgr. Michal Petr
Anotace
V originále
Objective: We aimed at assessing the predictive value of plasmatic Neutrophil Gelatinase Associated Lipocalin (pNGAL) at admission and severity scores to predict major adverse kidney events (MAKE, defined as death and/or need for renal replacement therapy (RRT) and/or non-renal recovery at day 90) in critically ill burn patients. Material and methods: Single-center cohort study in a burn critical care unit in a tertiary center, including all consecutive severely burn patients (total burned body surface >20%) from January 2012 until January 2015 with a pNGAL dosage at admission. Reclassification of patients was assessed by Integrated Discrimination Improvement (IDI). Measurements and results: 87 patients were included. Mean age was 47.7 (IQ 25-75: 33.4-65.2) years; total burn body surface area was 40 (IQ 25-75: 30-55) % and ICU mortality 36%. 39(44.8%) patients presented a MAKE, 32(88.9%) patients died at day 90. pNGAL was higher in the MAKE group (423 [IQ25-75: 327-518] pg/mL vs 184 [IQ25-75: 147-220] pg/mL, p<0.001). In multivariate analysis, pNGAL and abbreviated burn severity index (ABSI) remained associated with MAKE (OR 1.005 [CI 95% 1.0005-1.009], p=0.03 and OR 1.682 [CI95%1.038-2.726], p=0.035 respectively). Adding pNGAL to abbreviated burn severity index, simplified organ failure assessment and the simplified acute physiology score 2 did outperform clinical scores for the prediction of MAKE and AKI and for most severe forms of AKI and allowed a statistically significant reclassification of patients compared to ABSI for MAKE, RRT, AKI at Day 7 and AKI during hospitalization with a number of patients needed to screen to detect one extra episode of MAKE was 44, 13 for severe AKI and 15 for AKI. Conclusions: pNGAL at admission is associated with the risk of MAKE in this population, and outperform severity scores when associated. Interventional studies are now needed to assess if impact of biomarkers-guided strategies would improve outcome. (C) 2018 Elsevier Ltd and ISBI. All rights reserved.